Inositol for Health & Longevity

Created on 11/10/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Inositol, a dietary supplement the body makes, is studied mainly for blood sugar and hormonal health. Its clearest effects are modest improvements in fasting blood sugar, blood fats and blood pressure, mostly in a common ovarian hormone disorder, clustered metabolic risk factors and pregnancy. For people already improving metabolic health through diet and exercise, it is a low-risk, low-cost addition whose measurable effect lies in blood sugar regulation, not aging. (Full Review)

Protocol

Metabolic regimen
Myo-inositol 2 g twice daily
Used in postmenopausal women with metabolic syndrome and in pregnant women with PCOS
40:1 blend
2 g of inositols twice daily
40:1 myo- to D-chiro-inositol, the ratio that best restored ovulation among seven tested
Single versus split dose
Doses above 2 g usually split
Two or three portions, which also limits gastrointestinal effects; common practice
Time to effect
Menstrual and metabolic changes
3 to 6 months
Assessment point in trials
Blood pressure
Beyond 8 weeks
Larger reductions in pooled trials in metabolic syndrome and at 4,000 mg/day
Sleep quality
10 weeks
Self-rated sleep improved with 2,000 mg/day in one trial in pregnancy

Benefits

Contraindications
  • Extremely preterm infants (born before 28 weeks' gestation)
  • People with bipolar disorder outside psychiatric supervision, especially with irritability or mixed features
  • Women with PCOS seeking ovulation (D-chiro-inositol-only or high-D-chiro-inositol products)
  • Kidney failure (high doses)
Key Interactions
  • Lithium-associated psoriasis
  • Metformin
  • Alpha-lactalbumin
  • D-chiro-inositol, sorbitol and maltodextrin
  • Selenium
Theoretical (inferred from mechanism)
  • Insulin and sulfonylureas (glipizide)
  • SGLT2 inhibitors (empagliflozin)
  • Antihypertensives (lisinopril)
  • Glucose-lowering supplements (berberine)
  • Over-the-counter osmotic laxatives (polyethylene glycol)

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal discomfort at high doses
  • Low: Mood destabilization in bipolar disorder; mortality in extremely preterm infants; androgen excess from high-dose D-chiro-inositol
  • Speculative: Blunted AMPK signaling

Monitoring

Marker Target Why
Fasting glucose 70–99 mg/dL Expected to fall; safety check with diabetes drugs
Fasting insulin 2.6–24.9 µIU/mL Expected to fall with better insulin sensitivity
HOMA-IR No established target; track change from own baseline Expected to fall
Triglycerides Below 150 mg/dL Expected to fall
LDL cholesterol Below 100 mg/dL Expected to fall slightly
Total testosterone (women with PCOS) 15–70 ng/dL Expected to fall
SHBG (women with PCOS) 18–144 nmol/L Expected to rise
TSH (people on levothyroxine using selenium combinations) 0.4–4.0 mIU/L Safety check for an additive fall
Home blood pressure Not specified in the ER Cardiovascular baseline

Cadence: Baseline before starting, including one week of home blood pressure readings; fasting glucose and insulin at 3 months, then every 6–12 months together with a lipid panel; androgen tests at 3–6 months in women with PCOS; home glucose checks during the first 2–4 weeks with insulin or sulfonylureas; TSH recheck at 3 months with levothyroxine and a selenium combination

Qualitative Assessment

  • Menstrual regularity: cycle length and predictability in women with PCOS
  • Sleep quality: ease of falling back asleep and morning restfulness
  • Gastrointestinal tolerance: bloating, flatulence or loose stools, especially above 4 g/day
  • Mood and anxiety: frequency of panic or low mood; irritability or reduced sleep need in bipolar disorder